Publisher's Synopsis
Emerging technologies for cancer detection and diagnosis are providing more and more advance warning of pathologies of clinical significance. Research devoted to cancers are revealing new ways of finding and treating these complex diseases. This volume reviews a broad array of new technologies for cancer detection and diagnosis. While there are several clinical books describing cancer diagnosis, and general molecular analytical technologies, these books are not focused on cancer detection and diagnosis. The aim of this book is to describe emerging cancer detection and diagnosis technologies.
Key Features
Presents myriad new experimental cancer detection technologies
Describes technology so the reader may conduct similar analyses
Outlines clinical applications of technology for specific cancer and summarizes results
Discusses pitfalls and limitations, future trends and potential technological developments
Miguel Ossandon has a dual background in clinical laboratory and computer science. He started working in cancer research at the Lombardi Cancer Center at Georgetown University where he also began his undergraduate training in computer science. He has been working for the National Cancer Institute since 2007. Miguel received his master's degree at the George Washington University and PhD in computer science at the University of Maryland Baltimore County. As a program director in the Diagnostic Biomarkers and Technology Branch, he manages a grant portfolio related to computational modeling and machine learning approaches for cancer diagnosis, digital image processing/analysis, and microfluidic and circulating tumor cell technology.
Ben Prickril is a former US government official working at the US National Institutes of Health, National Cancer Institute. He has a background in medically related chemistry, microbiology, immunology, patenting and intellectual property, and global health. International research development includes experience in France, Turkey, Ukraine, Czech Republic and Burkina Faso. He received his PhD from the University of Georgia.
Avraham Rasooly is in the Division of Cancer Treatment and Diagnosis, National Cancer Institute. He has been responsible for developing research programs on new approaches for cancer therapy, including technologies for microbial-based cancer therapy. He received his PhD from Michigan State University.
